BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/12/2020 10:38:05 AM | Browse: 726 | Download: 1921
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 56283
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Basic Study
Article Title Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer
Manuscript Source Unsolicited Manuscript
All Author List Yan Yan, Hong-Wei Lin, Zhuo-Nan Zhuang, Ming Li and Sen Guo
Funding Agency and Grant Number
Funding Agency Grant Number
Beijing Tsinghua Changgung Hospital Fund 12015C1042
Bethune-Excellent Surgery Fund HZB-20181119-13
Chen Xiaoping Science and Technology Development Fund CXPJH11800004-021
Corresponding Author Sen Guo, PhD, Adjunct Professor, Department of General Surgery, Qilu Hospital of Shandong University, No. 107, Wenhuaxi Street, Jinan 250033, Shandong Province, China. guosen4321@163.com
Key Words Colon carcinoma; Chemotherapy; Nuclear factor kappa-B; Interleukin-1; Proliferation; Fluorouracil
Core Tip There was the feedback loop between up-regulated nuclear factor kappa-B (NF-κB) pathway and interleukin (IL)-1 which lead to the proliferation of cancer cells. Fluorouracil (5-FU), as a chemotherapy drug used to treat colon carcinoma cells, can activate the NF-κB pathway and lead to the resistance of chemotherapy. IL-1 receptor antagonist combined with 5-FU has stronger inhibitory effect on the proliferation of colon cancer cells due to the blocking of IL-1. It could provide an adjuvant chemotherapy plan for clinic and provide a theoretical basis for neoadjuvant chemotherapy.
Publish Date 2020-08-12 09:10
Citation Yan Y, Lin HW, Zhuang ZN, Li M, Guo S. Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer. World J Gastrointest Oncol 2020; 12(8): 877-892
URL https://www.wjgnet.com/1948-5204/full/v12/i8/877.htm
DOI https://dx.doi.org/10.4251/wjgo.v12.i8.877
Full Article (PDF) WJGO-12-877.pdf
Full Article (Word) WJGO-12-877.docx